Table 1

Dystonia and dyskinesias in 12 levodopa responsive patients with MSA-P

Patient	MSA subtype	Age at disease onset	Disease duration (y)	Levodopa naive dystonia	Initial levodopa response	Latency to introduction of levodopa (y)	Latency to levodopa induced dyskinesias (y)	Maximum levodopa dose (mg/day)	Site of dyskinesias	Time course of dyskinesias	Nature of dyskinesias
*Patients with MSA-P confirmed by postmortem.
1	MSA-P	61	8	Antecollis	Moderate	1	3	600	Cervical	Peak dose	Dystonic
2*	MSA-P	54	5	Dystonic arm	Excellent	1	4	500	Generalised	Peak dose	Choreodystonic
8	MSA-P	55	9	None	Excellent	2	3	500	Craniocervical	Peak dose	Dystonic
9	MSA-P	59	7	Writers cramp	Good	1	4	600	Craniocervical	Peak dose	Dystonic
10	MSA-P	64	5	None	Good	1	2	600	Both legs	Peak dose, off period	Choreodystonic
11	MSA-P	47	13	Antecollis	Excellent	3	1	750	Craniocervical	Peak dose, off period	Dystonic
12	MSA-P	74	5	Antecollis	Moderate	1	2	600	Cervical	Peak dose	Dystonic
13	MSA-P	54	6	None	Good	1	0.5	300	Craniocervical	Peak dose	Dystonic
14*	MSA-P	57	4	Dystonic foot posturing	Excellent	1	1	600	Left arm	End of dose	Dystonic
15	MSA-P	61	7	None	Good	2	3	400	Right leg	Peak dose	Choreatic
16*	MSA-P	47	4	None	Moderate	1	2	500	Generalised	Peak dose	Dystonic
18*	MSA-P	55	5	None	Moderate	1	3	700	Craniocervical	Peak dose	Dystonic
n=12		Mean 57.3 y	Mean 7.3 y			Mean 1.4 y	Mean 2.3 y	Mean 550 mg/day